☆ 4.6 Article

Inhaled D9-tetrahydrocannabinol does not enhance oxycodone- induced respiratory depression: randomised controlled trial in healthy volunteers

BRITISH JOURNAL OF ANAESTHESIA (2023)

Related references

Note: Only part of the references are listed.

Article Anesthesiology

Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression

Hyke Algera et al.

Summary: This study found that both oral and intravenous tianeptine do not have a respiratory stimulant effect in humans. In fact, intravenous tianeptine may worsen respiratory depression induced by opioids.

ANESTHESIOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia A Randomized Clinical Trial

Jeffry Florian et al.

Summary: This study aimed to investigate whether combining paroxetine or quetiapine with oxycodone would decrease the ventilatory response to hypercapnia, with findings showing that paroxetine plus oxycodone significantly decreased the ventilatory response on days 1 and 5, while quetiapine plus oxycodone did not have the same effect.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Pharmacology & Pharmacy

Brain Penetrant, but not Peripherally Restricted, Synthetic Cannabinoid 1 Receptor Agonists Promote Morphine-Mediated Respiratory Depression

Beth M. Wiese et al.

Summary: In this study, the roles of central and peripheral CB1 receptor activation on respiratory depression were explored, and it was found that the peripherally restricted CB1 agonist alone does not induce respiratory depression, while the combination of the peripheral CB1 agonist and morphine can attenuate morphine-induced respiratory depression. These findings support the use of a peripherally restricted CB1 agonist as a strategy to alleviate the respiratory depression associated with opioid therapy.

CANNABIS AND CANNABINOID RESEARCH (2022)

Add to Collection

Article Anesthesiology

Association between opioid-related deaths and prescribed opioid dose and psychotropic medicines in England: a case-crossover study

Teng-Chou Chen et al.

Summary: In the UK, a daily OMEQ dose greater than 120 mg and the concomitant use of psychotropic medicines were found to be associated with ORD5. Prescribers are advised to cautiously avoid prescribing opioids with a daily OMEQ dose greater than 120 mg and the combination of opioids and gabapentinoids, even with low opioid doses.

BRITISH JOURNAL OF ANAESTHESIA (2021)

Add to Collection

Review Health Care Sciences & Services

Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events

Martijn Boon et al.

ANNALS OF PALLIATIVE MEDICINE (2020)

Add to Collection

Article Pharmacology & Pharmacy

Medical Cannabis: Effects on Opioid and Benzodiazepine Requirements for Pain Control

Megan O'Connell et al.

ANNALS OF PHARMACOTHERAPY (2019)

Add to Collection

Article Anesthesiology

An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia

Tine van de Donk et al.

PAIN (2019)

Add to Collection

Article Anesthesiology

Esketamine counters opioid-induced respiratory depression

K. Jonkman et al.

BRITISH JOURNAL OF ANAESTHESIA (2018)

Add to Collection

Article Pharmacology & Pharmacy

Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys

Peter F. Weed et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2018)

Add to Collection

Article Neurosciences

Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability

Ziva D. Cooper et al.

NEUROPSYCHOPHARMACOLOGY (2018)

Add to Collection

Article Anesthesiology

Influence of Ethanol on Oxycodone-induced Respiratory Depression A Dose-escalating Study in Young and Elderly Individuals

Rutger van der Schrier et al.

ANESTHESIOLOGY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers

M. Roozekrans et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)

Add to Collection

Review Physiology

Structural and neurochemical changes in the maturation of the carotid body

Raffaele De Caro et al.

RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY (2013)

Add to Collection

Article Pediatrics

Synthetic Cannabis and Respiratory Depression

Felecia N. Jinwala et al.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2012)

Add to Collection

Review Pharmacology & Pharmacy

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin

R. G. Pertwee

BRITISH JOURNAL OF PHARMACOLOGY (2008)

Add to Collection

Article Chemistry, Medicinal

Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol

Arno Hazekamp et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2006)

Add to Collection

Article Multidisciplinary Sciences

Identification and functional characterization of brainstem cannabinoid CB2 receptors

MD Van Sickle et al.

SCIENCE (2005)

Add to Collection

Article Pharmacology & Pharmacy

Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats

T Pfitzer et al.

BRITISH JOURNAL OF PHARMACOLOGY (2004)

Add to Collection

Article Pharmacology & Pharmacy

Analysis of the respiratory effects of cannabinoids in rats

K Schmid et al.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2003)

Add to Collection

Article Pharmacology & Pharmacy

Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats

JR Padley et al.

BRITISH JOURNAL OF PHARMACOLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.